Abstract
摘要
相似文献
1
Levamisole--a cautionary note.左旋咪唑——一则警示说明。
Lancet. 1979 Aug 11;2(8137):291-2.
2
In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy.左旋咪唑免疫治疗期间对肺癌抗原细胞免疫增强的体外证据。
J Thorac Cardiovasc Surg. 1977 Feb;73(2):189-94.
3
[Levamisole -- a drug modifying immunologic phenomena].
Postepy Hig Med Dosw. 1979 Mar-Apr;33(2):125-46.
4
[Use of levamisole in nephrological practice (a review of the literature)].
Vrach Delo. 1982 May(5):12-6.
5
[Levamisole as an immunostimulant in primary lung cancer].
Pneumonol Pol. 1981 Jan;49(1):29-34.
6
Levamisole in a phase I trial.左旋咪唑的一项I期试验。
Cancer Treat Rep. 1976 Jul;60(7):963-4.
7
Levamisole: a synthetic immunopotentiator under evaluation.左旋咪唑：一种正在评估中的合成免疫增强剂。
Clin Bull. 1975;5(1):32-3.
8
Levamisole in cancer treatment: modifications in time of cellular immunity. (Preliminary report).
Boll Ist Sieroter Milan. 1979 Nov 30;58(5):435-9.
9
Letter: Levamisole.信件：左旋咪唑。
Lancet. 1975 Feb 15;1(7903):389.
10
Levamisole as an immunotherapeutic agent in the treatment of cancer.
World J Surg. 1977 Sep;1(5):597-604. doi: 10.1007/BF01556185.
Zotero 插件